Reference values for high-density lipoprotein particle size and volume by dynamic light scattering in a Brazilian population sample and their relationships with metabolic parameters

Carregando...
Imagem de Miniatura
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
ALEXANDRE, F.
ZAGO, V. H. S.
PANZOLDO, N. B.
PARRA, E. S.
SCHERRER, D. Z.
VENDRAME, F.
GOMES, E. I. L.
MARCATO, P. D.
Citação
CLINICA CHIMICA ACTA, v.442, p.63-72, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Current data indicate that the size of high-density lipoprotein (HDL) may be considered an important marker for cardiovascular disease risk. We established reference values of mean HDL size and volume in an asymptomatic representative Brazilian population sample (n = 590) and their associations with metabolic parameters by gender. Methods: Size and volume were determined in HDL isolated from plasma by polyethyleneglycol precipitation of apoB-containing lipoproteins and measured using the dynamic light scattering (DLS) technique. Results: Although the gender and age distributions agreed with other studies, the mean HDL size reference value was slightly lower than in some other populations. Both HDL size and volume were influenced by gender and varied according to age. HDL size was associated with age and HDL-C (total population); non- white ethnicity and CETP inversely (females); HDL-C and PLTP mass (males). On the other hand, HDL volume was determined only by HDL-C (total population and in both genders) and by PLTP mass (males). Conclusions: The reference values for mean HDL size and volume using the DLS technique were established in an asymptomatic and representative Brazilian population sample, as well as their related metabolic factors. HDL-C was a major determinant of HDL size and volume, which were differently modulated in females and in males.
Palavras-chave
Dynamic light scattering, HDL size, HDL volume, Reference values, Metabolic parameters
Referências
  1. Abeywardena MY, 2003, ATHEROSCLEROSIS, V171, P157, DOI 10.1016/S0021-9150(03)00157-6
  2. Arsenault BJ, 2010, CLIN CHEM, V56, P789, DOI 10.1373/clinchem.2009.140939
  3. Assmann G, 2004, CIRCULATION, V109, P8, DOI 10.1161/01.CIR.0000131512.50667.46
  4. Berg GA, 2001, MENOPAUSE, V8, P51, DOI 10.1097/00042192-200101000-00009
  5. BURT VL, 1995, HYPERTENSION, V25, P305
  6. Camont L, 2011, TRENDS MOL MED, V17, P594, DOI 10.1016/j.molmed.2011.05.013
  7. CHAPMAN MJ, 1981, J LIPID RES, V22, P339
  8. Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399
  9. Cheung MC, 2009, BBA-MOL CELL BIOL L, V1791, P206, DOI 10.1016/j.bbalip.2008.12.010
  10. Cullen P, 1997, CIRCULATION, V96, P2128
  11. da Silva IT, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-19
  12. DIAS VC, 1988, CLIN CHEM, V34, P2322
  13. DOBIASOVA M, 1992, J LIPID RES, V33, P1411
  14. Ehnholm C, 1986, Methods Enzymol, V129, P716
  15. El Harchaoui K, 2009, ANN INTERN MED, V150, P84
  16. Freedman DS, 2001, METABOLISM, V50, P370, DOI 10.1053/meta.2001.21027
  17. Freedman DS, 2004, CLIN CHEM, V50, P1189, DOI 10.1373/clinchem.2004.032763
  18. FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499
  19. Giribela AH, 2009, INT J GYNECOL OBSTET, V104, P117, DOI 10.1016/j.ijgo.2008.10.001
  20. GREENFIELD MS, 1980, METABOLISM, V29, P1095, DOI 10.1016/0026-0495(80)90221-8
  21. Huang R, 2011, NAT STRUCT MOL BIOL, V18, P416, DOI 10.1038/nsmb.2028
  22. (IBGE) IBdGeE, 2011, CAR ETN RAC POP
  23. Jauhiainen M, 2005, METHODS, V36, P97, DOI 10.1016/j.ymeth.2004.11.006
  24. JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032
  25. Johnson JL, 2004, ATHEROSCLEROSIS, V176, P371, DOI 10.1016/j.atherosclerosis.2004.05.018
  26. Kivatinitz SC, 1997, J NEUROCHEM, V69, P2102
  27. Koro CE, 2006, AM HEART J, V151, P755
  28. KUNITAKE ST, 1992, J LIPID RES, V33, P1807
  29. Lagrost L, 1996, J BIOL CHEM, V271, P19058
  30. Lagrost L, 1998, Methods Mol Biol, V110, P231
  31. Lima ES, 2004, CLIN CHEM, V50, P1086, DOI 10.1373/clinchem.2004.032383
  32. Linsel-Nitschke P, 2005, NAT REV DRUG DISCOV, V4, P193, DOI 10.1038/nrd1658
  33. Mackey RH, 2012, J AM COLL CARDIOL, V60, P508, DOI 10.1016/j.jacc.2012.03.060
  34. Mallol R, 2012, ANAL BIOANAL CHEM, V402, P2407, DOI 10.1007/s00216-011-5705-9
  35. Mantyselka P, 2012, ATHEROSCLEROSIS, V223, P239, DOI 10.1016/j.atherosclerosis.2012.05.005
  36. Matthews KA, 2001, STROKE, V32, P1104
  37. Mora S, 2009, CIRCULATION, V119, P931, DOI 10.1161/CIRCULATIONAHA.108.816181
  38. Musunuru K, 2009, ARTERIOSCL THROM VAS, V29, P1975, DOI 10.1161/ATVBAHA.109.190405
  39. Natori S, 2006, AM J ROENTGENOL, V186, pS357, DOI 10.2214/AJR.04.1868
  40. Olinto MTA, 2011, PUBLIC HEALTH NUTR, V14, P150, DOI 10.1017/S136898001000162X
  41. O'Neal D, 1998, J LIPID RES, V39, P2086
  42. PACKARD CJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P269, DOI 10.1016/0005-2760(79)90042-0
  43. Razavi AE, 2012, J RES MED SCI, V17, P1020
  44. Rosenson RS, 2011, CLIN CHEM, V57, P392, DOI 10.1373/clinchem.2010.155333
  45. Ross Reagan L, 2008, Curr Cardiol Rev, V4, P309, DOI 10.2174/157340308786349462
  46. Sakurai T, 2010, ANN CLIN BIOCHEM, V47, P476, DOI 10.1258/acb.2010.010100
  47. Santos PCJL, 2010, BLOOD CELL MOL DIS, V45, P302, DOI 10.1016/j.bcmd.2010.08.008
  48. Silva RAGD, 2008, P NATL ACAD SCI USA, V105, P12176, DOI 10.1073/pnas.0803626105
  49. Stahlman M, 2013, BBA-MOL CELL BIOL L, V1831, P1609, DOI 10.1016/j.bbalip.2013.07.009
  50. Sviridov D, 2008, J ATHEROSCLER THROMB, V15, P52
  51. Toth Peter P, 2012, Vasc Health Risk Manag, V8, P39, DOI 10.2147/VHRM.S22601
  52. Vaccarino V, 2011, CARDIOVASC RES, V90, P9, DOI 10.1093/cvr/cvq394
  53. Vergeer M, 2010, CIRCULATION, V122, P470, DOI 10.1161/CIRCULATIONAHA.109.912519
  54. Villard EF, 2012, ARTERIOSCL THROM VAS, V32, P2341, DOI 10.1161/ATVBAHA.112.252841
  55. Watanabe H, 2006, ARTERIOSCL THROM VAS, V26, P897, DOI 10.1161/01.ATV.0000209577.04246.c0
  56. WILLIAMS PT, 1993, ARTERIOSCLER THROMB, V13, P1654